M. Kaminski, A. Zelenetz, O. Press, M. Saleh, J. Leonard et al., Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin???s Lymphomas, Journal of Clinical Oncology, vol.19, issue.19, pp.3918-3928, 2001.
DOI : 10.1200/JCO.2001.19.19.3918

T. Witzig, L. Gordon, F. Cabanillas, M. Czuczman, C. Emmanouilides et al., Randomized Controlled Trial of Yttrium-90???Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin???s Lymphoma, Journal of Clinical Oncology, vol.20, issue.10, pp.2453-2463, 2002.
DOI : 10.1200/JCO.2002.11.076

R. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. Toder et al., Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y- Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?, J Nucl Med, vol.44, pp.2000-2018, 2003.

J. Mach, S. Carrel, M. Forni, J. Ritschard, A. Donath et al., Tumor Localization of Radio-Labeled Antibodies against Carcinoembryonic Antigen in Patients with Carcinoma, New England Journal of Medicine, vol.303, issue.1, pp.5-10, 1980.
DOI : 10.1056/NEJM198007033030102

D. Goldenberg, F. Deland, E. Kim, S. Bennett, F. Primus et al., Use of Radio-Labeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning, New England Journal of Medicine, vol.298, issue.25, pp.1384-1388, 1978.
DOI : 10.1056/NEJM197806222982503

M. Ychou, A. Pèlegrin, P. Faurous, B. Robert, J. Saccavini et al., Phase-I/II radio-immunotherapy study with iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab???)2 in patients with non-resectable liver metastases from colorectal cancer, International Journal of Cancer, vol.14, issue.4, pp.615-619, 1998.
DOI : 10.1002/(SICI)1097-0215(19980209)75:4<615::AID-IJC20>3.0.CO;2-6

S. Denardo, O. Grady, L. Richman, C. Goldstein, D. et al., Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody, Anticancer Res, vol.17, pp.1745-1751, 1997.

T. Behr, T. Liersch, L. Greiner-bechert, F. Griesinger, M. Behe et al., Radioimmunotherapy of small-volume disease of metastatic colorectal cancer, Cancer, vol.57, issue.S4, pp.1373-1381, 2002.
DOI : 10.1002/cncr.10308

J. Deacon, M. Peckham, and G. Steel, The radioresponsiveness of human tumours and the initial slope ofthe cell survival curve, Radiotherapy and Oncology, vol.2, issue.4, pp.317-323, 1984.
DOI : 10.1016/S0167-8140(84)80074-2

G. Steel, T. Mcmillan, and J. Peacock, The 5Rs of Radiobiology, International Journal of Radiation Biology, vol.5, issue.6, pp.1045-1048, 1989.
DOI : 10.1080/09553008914552491

H. Zhu, L. Baxter, and R. Jain, Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies, J Nucl Med, vol.38, pp.731-741, 1997.

J. Mach, A. Pèlegrin, and F. Buchegger, Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors, Current Opinion in Immunology, vol.3, issue.5, pp.685-693, 1991.
DOI : 10.1016/0952-7915(91)90097-K

J. Chatal and C. Hoefnagel, Radionuclide therapy, The Lancet, vol.354, issue.9182, pp.931-935, 1999.
DOI : 10.1016/S0140-6736(99)06002-X

J. Wong, S. Shibata, L. Williams, C. Kwok, A. Liu et al., A Phase I trial of 90Y-anti-carcinoembry- onic antigen chimeric T84.66 radioimmunotherapy with 5- fluorouracil in patients with metastatic colorectal cancer, Clin Cancer Res, vol.9, pp.5842-5852, 2003.

G. Hajjar, R. Sharkey, J. Burton, C. Zhang, D. Yeldell et al., Phase I Radioimmunotherapy Trial with Iodine-131???Labeled Humanized MN-14 Anti???Carcinoembryonic Antigen Monoclonal Antibody in Patients with Metastatic Gastrointestinal and Colorectal Cancer, Clinical Colorectal Cancer, vol.2, issue.1, pp.31-42, 2002.
DOI : 10.3816/CCC.2002.n.009

L. Saltz, J. Cox, C. Blanke, L. Rosen, L. Fehrenbacher et al., Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.343, issue.13, pp.905-914, 2000.
DOI : 10.1056/NEJM200009283431302

J. Douillard, D. Cunningham, A. Roth, M. Navarro, R. James et al., Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, The Lancet, vol.355, issue.9209, pp.1041-1047, 2000.
DOI : 10.1016/S0140-6736(00)02034-1

A. De-gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi et al., Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer, Journal of Clinical Oncology, vol.18, issue.16, pp.2938-2947, 2000.
DOI : 10.1200/JCO.2000.18.16.2938

F. Buchegger, J. Mach, A. Pèlegrin, M. Gillet, C. Vogel et al., Bischof-Delaloye A: Radiolabeled chimeric anti- CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma, J Nucl Med, vol.36, pp.420-429, 1995.

L. Stewart, S. Young, G. Watson, S. Mather, P. Bates et al., Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen, Cancer Immunology, Immunotherapy, vol.47, issue.6, pp.299-306, 1999.
DOI : 10.1007/s002620050534

M. Mendez, L. Green, J. Corvalan, X. Jia, C. Maynard-currie et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nature Genetics, vol.91, issue.2, pp.146-156, 1997.
DOI : 10.1074/jbc.270.6.2716

A. Terskikh, J. Mach, and A. Pèlegrin, Marked increase in the secretion of a fully antigenic recombinant carcinoembryonic antigen obtained by deletion of its hydrophobic tail, Molecular Immunology, vol.30, issue.10, pp.921-927, 1993.
DOI : 10.1016/0161-5890(93)90016-5

F. Buchegger, C. Pfister, K. Fournier, F. Prevel, M. Schreyer et al., Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments., Journal of Clinical Investigation, vol.83, issue.5, pp.1449-1456, 1989.
DOI : 10.1172/JCI114037

N. Hardman, L. Gill, D. Winter, R. Wagner, K. Hollis et al., Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen, International Journal of Cancer, vol.84, issue.3, pp.424-433, 1989.
DOI : 10.1002/ijc.2910440308

M. Nap, M. Hammarstrom, O. Bormer, S. Hammarstrom, C. Wagener et al., Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen, Cancer Res, vol.52, pp.2329-2339, 1992.

S. Hammarstrom, J. Shively, R. Paxton, B. Beatty, A. Larson et al., Antigenic sites in carcinoembryonic antigen, Cancer Res, vol.49, pp.4852-4858, 1989.

L. Edelman, C. Margaritte, H. Chaabihi, E. Monchatre, D. Blanchard et al., Obtaining a functional recombinant anti-rhesus (D) antibody using the baculovirus-insect cell expression system, Immunology, vol.91, issue.1, pp.13-19, 1997.
DOI : 10.1046/j.1365-2567.1997.00219.x

B. Tom, L. Rutzky, M. Jakstys, R. Oyasu, C. Kaye et al., Human colonic adenocarcinoma cells. I. Establishment and description of a new line, pp.180-191, 1976.
DOI : 10.1007/bf02796440

A. Leconte, V. Garambois, M. Ychou, B. Robert, D. Pourquier et al., Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model, British Journal of Cancer, vol.80, issue.9, pp.1373-1379, 1999.
DOI : 10.1038/sj.bjc.6690531

B. Hendrickson, D. Conner, D. Ladd, D. Kendall, J. Casanova et al., Altered hepatic transport of immunoglobulin A in mice lacking the J chain, Journal of Experimental Medicine, vol.182, issue.6, pp.1905-1911, 1995.
DOI : 10.1084/jem.182.6.1905

J. Reichert, Monoclonal antibodies in the clinic, Nature Biotechnology, vol.19, issue.9, pp.819-822, 2001.
DOI : 10.1038/nbt0901-819

X. Yang, X. Jia, J. Corvalan, P. Wang, and C. Davis, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy, Critical Reviews in Oncology/Hematology, vol.38, issue.1, pp.17-23, 2001.
DOI : 10.1016/S1040-8428(00)00134-7

U. Vanhoefer, M. Tewes, F. Rojo, O. Dirsch, N. Schleucher et al., Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.1, pp.175-184, 2004.
DOI : 10.1200/JCO.2004.05.114

C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris et al., -Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, vol.20, issue.3, pp.719-726, 2002.
DOI : 10.1200/JCO.2002.20.3.719
URL : https://hal.archives-ouvertes.fr/hal-00159653

A. Forero and A. Lobuglio, History of antibody therapy for non-Hodgkin???s lymphoma, Seminars in Oncology, vol.30, pp.1-5, 2003.
DOI : 10.1053/j.seminoncol.2003.10.002

K. Tsukazaki, K. Kuroda, K. Mochizuki, K. Kubushiro, T. Fukuchi et al., A human monoclonal antibody to carbohydrate moiety of carcinoembryonic antigen, Hum Antibodies Hybridomas, vol.6, pp.145-152, 1995.

T. Imakiire, M. Kuroki, H. Shibaguchi, H. Abe, Y. Yamauchi et al., Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen, International Journal of Cancer, vol.6, issue.4, pp.564-570, 2004.
DOI : 10.1002/ijc.11608

H. Durbin, S. Young, L. Stewart, F. Wrba, A. Rowan et al., An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3., Proceedings of the National Academy of Sciences, vol.91, issue.10, pp.4313-4317, 1994.
DOI : 10.1073/pnas.91.10.4313

B. Robert, J. Mach, J. Mani, M. Ychou, S. Folli et al., Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor a, Cancer Res, vol.56, pp.4758-4765, 1996.

B. Robert, M. Dorvillius, F. Buchegger, V. Garambois, J. Mani et al., Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA), International Journal of Cancer, vol.75, issue.2, pp.285-291, 1999.
DOI : 10.1002/(SICI)1097-0215(19990412)81:2<285::AID-IJC19>3.0.CO;2-T

V. Langmuir, H. Mendonca, and D. Woo, Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-anti- body therapy efficacy in multicell spheroids, Cancer Research, vol.52, pp.4728-4734, 1992.

J. Schlom, D. Eggensperger, D. Colcher, A. Molinolo, D. Houchens et al., Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates, Cancer Research, vol.52, pp.1067-1072, 1992.

T. Behr, R. Sharkey, M. Juweid, R. Dunn, Z. Ying et al., Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies, J Nucl Med, vol.38, pp.409-418, 1997.

D. Delacroix, G. Malburny, and J. Vaerman, Hepatobiliary transport of plasma IgA in the mouse: contribution to clearance of intravascular IgA, European Journal of Immunology, vol.74, issue.9, pp.893-899, 1985.
DOI : 10.1002/eji.1830150906

T. Koertge and J. Butler, Dimeric Mouse IgA is Transported into Rat Bile Five Times More Rapidly than into Mouse Bile, Scandinavian Journal of Immunology, vol.127, issue.5, pp.567-574, 1986.
DOI : 10.1084/jem.150.6.1538

P. Borchardt, S. Quadri, R. Freedman, and H. Vriesendorp, Indium- 111-and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice, J Nucl Med, vol.39, pp.476-484, 1998.

P. Borchardt, S. Quadri, R. Freedman, and H. Vriesendorp, Intraperitoneal Radioimmunotherapy with Human Monoclonal IGM in Nude Mice with Peritoneal Carcinomatosis, Cancer Biotherapy & Radiopharmaceuticals, vol.15, issue.1, pp.53-64, 2000.
DOI : 10.1089/cbr.2000.15.53

P. Brandtzaeg, Role of J Chain and Secretory Component in Receptor-Mediated Glandular and Hepatic Transport of Immunoglobulins in Man, Scandinavian Journal of Immunology, vol.75, issue.2, pp.111-146, 1985.
DOI : 10.1084/jem.155.3.647

J. Barbet, P. Peltier, S. Bardet, J. Vuillez, I. Bachelot et al., Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti- DTPA-indium bispecific antibody, J Nucl Med, vol.39, pp.1172-1178, 1998.

M. Gutowski, M. Carcenac, D. Pourquier, C. Larroque, P. Rouanet et al., Intraoperative immunophotodetection for radical resection of cancer : evaluation in an experimental model, Clin Cancer Res, vol.7, pp.1142-1148, 2001.

B. Robert, P. Guillaume, I. Luescher, P. Romero, and J. Mach, Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes, European Journal of Immunology, vol.191, issue.11, pp.3165-3170, 2000.
DOI : 10.1002/1521-4141(200011)30:11<3165::AID-IMMU3165>3.0.CO;2-R

B. Robert, P. Guillaume, I. Luescher, M. Doucey, J. Cerottini et al., Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide coupled to antibody fragments, Cancer Immunity, vol.1, issue.2, 2001.

X. Xu, P. Clarke, G. Szalai, J. Shively, L. Williams et al., Targeting and therapy of carcinoembryonic antigenexpressing tumors in transgenic mice with an antibodyinterleukin 2 fusion protein, Cancer Res, vol.60, pp.4475-4484, 2000.